Trattamento del carcinoma ovarico con interferone α2b somministrato per via intraperitoneale

Translated title of the contribution: Intraperitoneal interferon α2b treatment of ovarian carcinoma

D. Ambrosio, L. Piscopo, C. Lauro, M. Rotondi, E. Gallo, F. Balbi

Research output: Contribution to journalArticlepeer-review

Abstract

Background. Pharmacokinetic studies have confirmed that for many chemotherapeutic agents a substantial pharmacological advantage can be achieved using the intraperitoneal route. Aim of this study is to evaluate the efficacy of intraperitoneal interferon α2b chemotherapy to treat ovarian cancer. Methods. Forty-four patients affected by ovarian cancer have been submitted to intraperitoneal interferon α2b chemotherapy from October 1989 to May 1996 at the Gynecology and Obstetric Institute of the Second University of Naples. Intraperitoneal route has been obtained through a catheter in left iliac fossa. Drugs have been solved in 2000 ml of physiologic solution to obtain a better distribution into the peritoneal fluid. Results. Three patients of 15 not-pre-medicated and 16 of 24 pre-medicated have obtained complete anatomo-pathological resolution. No complicances have been checked about catheter. Only two patients have stopped the therapy for asthenia; all the others have well tolerated interferon. Conclusions. Our study shows the very low toxicity of interferon associated to a good tolerance of the intraperitoneal catheter and therefore we retain that intraperitoneal chemotherapy with interferon α2b improves the prognosis of patients with minimal ovarian cancer after systemical chemotherapy.

Translated title of the contributionIntraperitoneal interferon α2b treatment of ovarian carcinoma
Original languageItalian
Pages (from-to)67-71
Number of pages5
JournalMinerva Ginecologica
Volume53
Issue number1 SUPPL. 1
Publication statusPublished - Feb 2001

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Fingerprint Dive into the research topics of 'Intraperitoneal interferon α2b treatment of ovarian carcinoma'. Together they form a unique fingerprint.

Cite this